公开(公告)号：US09447058B2

公开(公告)日：2016-09-20

申请号：US14878749

申请日：2015-10-08

Applicant: Duke University ,  Chaperone Therapeutics, Inc.

Inventor： Dennis J. Thiele ,  Daniel W. Neef ,  Jose S. Mendoza

IPC: C07D277/42 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/426 ,  A61K45/06 ,  C07D231/40 ,  C07D277/60 ,  C07D409/04 ,  C07K14/47 ,  C07C211/01 ,  C07D231/38 ,  C07D277/38 ,  C07D405/14 ,  C07D413/12

CPC classification number: C07D231/40 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/426 ,  A61K45/06 ,  C07C211/01 ,  C07C211/29 ,  C07D231/38 ,  C07D277/38 ,  C07D277/42 ,  C07D277/46 ,  C07D277/60 ,  C07D405/14 ,  C07D409/04 ,  C07D413/12 ,  C07K14/47 ,  A61K2300/00

Abstract: The present invention relates to 1,3-thiazole compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof.

公开(公告)号：US20160024035A1

公开(公告)日：2016-01-28

申请号：US14878749

申请日：2015-10-08

Applicant: Duke University ,  Chaperone Therapeutics, Inc.

Inventor： Dennis J. Thiele ,  Daniel W. Neef ,  Jose S. Mendoza

IPC: C07D277/42

CPC classification number: C07D231/40 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/426 ,  A61K45/06 ,  C07C211/01 ,  C07C211/29 ,  C07D231/38 ,  C07D277/38 ,  C07D277/42 ,  C07D277/46 ,  C07D277/60 ,  C07D405/14 ,  C07D409/04 ,  C07D413/12 ,  C07K14/47 ,  A61K2300/00

Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.

公开(公告)号：US20170000768A1

公开(公告)日：2017-01-05

申请号：US15269584

申请日：2016-09-19

Applicant: Duke University ,  Chaperone Therapeutics, Inc.

Inventor： Dennis J. Thiele ,  Daniel W. Neef ,  Jose S. Mendoza

IPC: A61K31/415 ,  A61K31/426 ,  A61K31/4155

CPC classification number: C07D231/40 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/426 ,  A61K45/06 ,  C07C211/01 ,  C07C211/29 ,  C07D231/38 ,  C07D277/38 ,  C07D277/42 ,  C07D277/46 ,  C07D277/60 ,  C07D405/14 ,  C07D409/04 ,  C07D413/12 ,  C07K14/47 ,  A61K2300/00

Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.

Abstract translation: 本发明涉及HSF活化化合物，其发现方法及其研究和治疗用途，以及其药学上可接受的盐，溶剂合物，螯合物，非共价复合物，前药，混合物（包括R和S对映体形式和外消旋 其混合物）及其药物制剂。 特别地，本发明提供能够促进HSF1同源三聚化的化合物，以及使用这些化合物作为治疗剂来治疗与不规则HSF1活性相关的许多病症的方法。

公开(公告)号：US20160221958A1

公开(公告)日：2016-08-04

申请号：US15131938

申请日：2016-04-18

Applicant: DUKE UNIVERSITY ,  CHAPERONE THERAPEUTICS, INC

Inventor： Dennis J. Thiele ,  Daniel W. Neef ,  Jose Serafin Mendoza

IPC: C07D231/40 ,  C07D409/04 ,  C07C211/29 ,  C07D277/46 ,  C07D277/60 ,  C07D413/12 ,  C07D405/14 ,  C07D277/42

CPC classification number: C07D231/40 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/426 ,  A61K45/06 ,  C07C211/01 ,  C07C211/29 ,  C07D231/38 ,  C07D277/38 ,  C07D277/42 ,  C07D277/46 ,  C07D277/60 ,  C07D405/14 ,  C07D409/04 ,  C07D413/12 ,  C07K14/47 ,  A61K2300/00

Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.

Abstract translation: 本发明涉及HSF活化化合物，其发现方法及其研究和治疗用途，以及其药学上可接受的盐，溶剂合物，螯合物，非共价复合物，前药，混合物（包括R和S对映体形式和外消旋 其混合物）及其药物制剂。 特别地，本发明提供能够促进HSF1同源三聚化的化合物，以及使用这些化合物作为治疗剂来治疗与不规则HSF1活性相关的许多病症的方法。

公开(公告)号：US20170227553A1

公开(公告)日：2017-08-10

申请号：US15501765

申请日：2015-08-04

Applicant: Duke University

Inventor： Dennis J. Thiele ,  Rocio Gomez-Pastor ,  Daniel W. Neef

IPC: G01N33/68 ,  A61K31/404 ,  A61K31/501 ,  A61K31/4184 ,  A61K31/122 ,  A61K31/4035

CPC classification number: G01N33/6896 ,  A61K31/122 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/4162 ,  A61K31/4184 ,  A61K31/47 ,  A61K31/501 ,  A61K31/53 ,  G01N33/60 ,  G01N2440/14 ,  G01N2800/52

Abstract: Provided herein are methods for identifying and treating subjects having conditions involving reduced HSF1 activity (e.g., diminished HSF1 activity, diminished HSF1 protein levels, increased HSF1 Ser303 phosphorylation, increased HSF1 Ser307 phosphorylation) or conditions that benefit from increasing HSF1 abundance or activity beyond physiological levels.

公开(公告)号：US09718784B2

公开(公告)日：2017-08-01

申请号：US15131938

申请日：2016-04-18

Applicant: DUKE UNIVERSITY ,  CHAPERONE THERAPEUTICS, INC

Inventor： Dennis J. Thiele ,  Daniel W. Neef ,  Jose Serafin Mendoza

IPC: C07D231/38 ,  C07D231/40 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/426 ,  A61K45/06 ,  C07D277/42 ,  C07D277/60 ,  C07D409/04 ,  C07K14/47 ,  C07C211/01 ,  C07D277/38 ,  C07D405/14 ,  C07D413/12 ,  C07C211/29 ,  C07D277/46

CPC classification number: C07D231/40 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/426 ,  A61K45/06 ,  C07C211/01 ,  C07C211/29 ,  C07D231/38 ,  C07D277/38 ,  C07D277/42 ,  C07D277/46 ,  C07D277/60 ,  C07D405/14 ,  C07D409/04 ,  C07D413/12 ,  C07K14/47 ,  A61K2300/00

Abstract: The present invention relates to substituted pyrazole compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof) and pharmaceutical formulations thereof.

公开(公告)号：US09717709B2

公开(公告)日：2017-08-01

申请号：US15269584

申请日：2016-09-19

Applicant: Duke University ,  Chaperone Therapeutics, Inc.

Inventor： Dennis J. Thiele ,  Daniel W. Neef ,  Jose S. Mendoza

IPC: C07D231/10 ,  C07D409/04 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/426 ,  A61K45/06 ,  C07D231/40 ,  C07D277/42 ,  C07D277/60 ,  C07K14/47 ,  C07C211/01 ,  C07D231/38 ,  C07D277/38 ,  C07D405/14 ,  C07D413/12 ,  C07C211/29 ,  C07D277/46

CPC classification number: C07D231/40 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/426 ,  A61K45/06 ,  C07C211/01 ,  C07C211/29 ,  C07D231/38 ,  C07D277/38 ,  C07D277/42 ,  C07D277/46 ,  C07D277/60 ,  C07D405/14 ,  C07D409/04 ,  C07D413/12 ,  C07K14/47 ,  A61K2300/00

Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.